← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,592	-7	-0.3%	$220B
2	2 Pfizer PFE $166B	2,204	-27	-1%	$152B
3	3 Merck MRK $364B	2,017	+24	+1%	$121B
4	4 AbbVie ABBV $501B	1,996	-20	-1%	$99.2B
5	5 Amgen AMGN $230B	1,763	+13	+0.7%	$99.8B
6	6 Bristol-Myers Squibb BMY $121B	1,691	-56	-3%	$66.3B
7	7 Gilead Sciences GILD $190B	1,523	-42	-3%	$72.7B
8	8 Novartis NVS $279B	987	-26	-3%	$19.3B
9	9 GSK GSK $95.9B	787	+8	+1%	$11.1B
10	10 Regeneron Pharmaceuticals REGN $80.1B	624	+4	+0.6%	$25.1B
11	11 AstraZeneca AZN $251B	531	+11	+2%	$14.4B
12	12 Incyte INCY $22.6B	453	-47	-9%	$13.2B
13	13 Jazz Pharmaceuticals JAZZ $13.6B	376	+53	+16%	$9.69B
14	14 DELISTED Exact Sciences EXAS	348	+29	+9%	$6.41B
15	15 Exelixis EXEL $15.1B	304	+9	+3%	$5.25B
16	SGEN 16 DELISTED Seagen Inc. Common Stock SGEN	295	+8	+3%	$11B
17	17 Myriad Genetics MYGN $397M	258	-2	-0.8%	$2.75B
18	18 Qiagen QGEN $9.41B	232	+1	+0.4%	$5.42B
19	19 Opko Health OPK $1.02B	214	-13	-6%	$670M
20	CLVS 20 DELISTED Clovis Oncology, Inc. CLVS	210	-19	-8%	$2.47B
21	21 DELISTED Immunogen Inc IMGN	198	-6	-3%	$1.22B
22	22 Halozyme HALO $13.3B	193	-16	-8%	$2.07B
23	23 Kyntra Bio KYNB $22.6M	192	-1	-0.5%	$4.05B
24	24 DELISTED Eagle Pharmaceuticals, Inc. EGRX	183	+9	+5%	$1.16B
25	25 DELISTED Blueprint Medicines BPMC	181	+6	+3%	$2.84B